CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
|
|
- Britney Alexina Maxwell
- 5 years ago
- Views:
Transcription
1 CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and Advanced Concepts Institute. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 Category 1 credits toward the AMA Physician s Recognition Award. Each physician should claim only those credits that he/she Continuing Education Accreditation The Philadelphia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Philadelphia College of Pharmacy designates this educational activity (# H01) acceptable for 1.8 continuing education credits (0.18 CEUs). Each pharmacist should claim only those credits that he/she Method of Participation There are no fees for participating and receiving credit for this activity. During the period October 15, 2004, through October 31, 2006, participants must (1) read the educational objectives and faculty disclosures; (2) study the educational activity; (3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; (4) complete the evaluation form; and (5) mail or fax the evaluation form with answer key to Advanced Concepts Institute, 600 South 43rd Street, Philadelphia, PA 19104, Fax (215) A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks. Media Printed Journal Supplement Instructions After reading The Management of Respiratory Tract Infections: A Focus on Appropriate Antibiotic Utilization, complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (a minimum score of 70%) the examination at the conclusion of the program. 1. Which of the following community-acquired respiratory tract infections (CARTIs) can be described as an infection of the lung parenchyma? a) Acute exacerbations of chronic bronchitis b) Acute rhinosinusitis c) Community-acquired pneumonia (CAP) d) Acute otitis media 2. What percentage of Streptococcus pneumoniae is multidrug resistant? a) 20% b) 22% c) 34% d) 35% 3. Which of the following pathogens are responsible for up to 20% of CAP cases? a) S pneumoniae, Haemophilus influenzae, Moraxella catarrhalis b) Legionella spp, H influenzae, S pneumoniae c) S pneumoniae, Mycoplasma pneumoniae, Legionella spp d) Legionella spp, M pneumoniae, Chlamydia pneumoniae 4. An agent expected to successfully combat a CARTI should cover which of the following organisms? a) Susceptible and resistant strains of typical respiratory pathogens as well as atypical respiratory pathogens b) Susceptible and resistant strains of typical respiratory pathogens, atypical respiratory pathogens, as well as gram-negative pathogens c) Susceptible strains of typical respiratory pathogens, atypical respiratory pathogens, as well as gram-negative pathogens d) Resistant strains of typical respiratory pathogens, atypical respiratory pathogens, as well as gramnegative pathogens 5. Which of the following forms of bacterial resistance is relevant to antibiotic structure? a) Prolonged exposure of a pathogen to subtherapeutic levels of an antibiotic selecting for resistant strains b) Mutation of the antibiotic binding site preventing antibiotic action c) Exposure of pathogens to suboptimal bacterial kill leaving stronger/resistant pathogens to survive d) Exposure to bacteriostatic agents 6. What 2 antibiotic characteristics are key in the development of antibiotic resistance? a) Bactericidal activity and the potential to induce future antibiotic resistance b) Spectrum of activity and half-life c) Spectrum of activity and the potential to induce future antibiotic resistance d) Bactericidal activity and potency S408 THE AMERICAN JOURNAL OF MANAGED CARE OCTOBER 2004
2 CME/CE QUIZ 7. What chemical structure modification enables the ketolides to overcome the most common forms of bacterial resistance? a) Addition of an alkyl-aryl group at positions 11/12 b) Addition of a 6-methoxy group c) Removal of the D-cladinose moiety d) Replacement of the L-cladinose moiety with a 3-ketone 8. How do the ketolides exert their antimicrobial activity? a) Inhibition of deoxyribonucleic acid gyrase and topoisomerase I.V. b) Prevention of the translation of bacterial messenger ribonucleic acid c) Inhibition of the biosynthesis of cell wall mucopeptide d) Competitive antagonism of folic acid synthesis 9. What percentage of multidrug-resistant S pneumoniae isolates was susceptible to telithromycin at 1 mg/ml in the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study? a) >99% b) 95%-99% c) 90%-94% d) <90% 10. Which of the following medications are contraindicated with the coadministration of telithromycin? a) Pimozide and cisapride b) Itraconazole and ketoconazole c) Simvastatin and lovastatin d) Theophylline and paroxetine 11. Clinical trials of telithromycin have found that telithromycin 800 mg once daily for 5 days was. a) As effective as cefuroxime axetil 500 mg twice daily for 5 days b) More effective than trimethoprim/sulfamethoxazole 160 mg/800 mg 4 times daily for 10 days c) Less effective than clarithromycin 500 mg twice daily for 10 days d) As effective as amoxicillin/clavulanate 500 mg/125 mg 3 times daily for 10 days 12. Which of the following was the most common treatment-related adverse event in patients receiving telithromycin? a) Dizziness b) Vomiting c) Diarrhea d) Headache 13. In a rank order of the leading causes of death in the United States, CAP ranks. a) 4th b) 5th c) 6th d) 7th 14. In an examination of an administrative claims database of a national employer from the years , the hospitalization rate for patients younger than 65 years of age for CAP was. a) 11.8% b) 19.6% c) 28.4% d) 39.2% 15. The majority of the treatment costs (93.7%) for acute exacerbations of chronic bronchitis (AECB) are the result of. a) Outpatient costs b) Medication costs c) Hospital costs d) Physician visits 16. Current recommendations from the Infectious Diseases Society of America for empiric antibiotic selection in CAP are based on. a) Severity of illness, resistance patterns of S pneumoniae, comorbid conditions, and cost of therapy b) Severity of illness, pathogen probabilities, comorbid conditions, and cost of therapy c) Severity of illness, pathogen probabilities, resistance patterns of S pneumoniae, and cost of therapy d) Severity of illness, pathogen probabilities, resistance patterns of S pneumoniae, and comorbid conditions 17. In calculating the true economic cost of pharmaceuticals, which of the following indirect costs should be considered? a) Costs of medical care, adverse events, medication acquisition, clinical monitoring b) Costs of medical care, adverse events, medication acquisition, treatment failures c) Costs of medical care, adverse events, clinical monitoring, treatment failures d) Costs of medical care, medication acquisition, clinical monitoring, treatment failures 18. When examining health economic outcomes data for various antibiotics used to treat CAP and AECB, what factor drove significant cost differences? a) I.V. antibiotic use b) Length of hospital stay c) Emergency room visits d) Outpatient visits VOL. 10, NO. 12, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S409
3 CME/CE EVALUATION The Management of Respiratory Tract Infections: A Focus on Appropriate Antibiotic Utilization EVALUATION FORM ACPE Number: H01 Mail or fax this form by October 31, 2006: (Mail) Advanced Concepts Institute 600 South 43rd Street, Philadelphia, PA (Fax) NAME AND ADDRESS INFORMATION (please print clearly) Pharmacist Physician Other LAST NAME FIRST NAME INITIAL CREDENTIALS POSITION/TITLE MAILING ADDRESS CITY STATE ZIP ADDRESS TELEPHONE (WITH AREA CODE) FAX (WITH AREA CODE) EVALUATION Excellent Good Satisfactory Poor Accuracy and timeliness of content Relevance to your clinical practice Freedom from commercial bias Relationship of objectives to overall purpose of activity Relevance of the content to the learning objectives Extent to which the learning objectives were met Explain the various community-acquired respiratory tract infections and current treatment options Describe the emerging resistance patterns of respiratory tract pathogens to antibiotics in both hospital- and community-acquired infections Evaluate current and future pharmacologic options for the management of respiratory tract infections by comparing and contrasting antibiotic profile characteristics such as spectrum of coverage, risk of resistance, pharmacokinetics, and pharmacodynamics A103 S410 THE AMERICAN JOURNAL OF MANAGED CARE OCTOBER 2004
4 CME/CE EVALUATION EVALUATION (continued) Excellent Good Satisfactory Poor Discuss formulary decision-making strategies that may limit antimicrobial resistance and improve outcomes Discuss the pharmacoeconomic outcomes of various antibiotic regimens Effectiveness of the teaching methods Effectiveness of the learning materials Level of difficulty of this activity Did this activity add to your knowledge? Yes Somewhat No Will this information help in your practice? Yes Somewhat No Comments or topics for future activities The Management of Respiratory Tract Infections: A Focus on Appropriate Antibiotic Utilization ANSWERS (refer to the CME/CE Quiz on page S408) a b c d a b c d a b c d a b c d A103 VOL. 10, NO. 12, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S411
5 The Management of Respiratory Tract Infections: A Focus on Appropriate Antibiotic Utilization GOAL The goal of the supplement will be to educate managed care professionals about the influence of inappropriate antibiotic utilization for the treatment of community-acquired respiratory tract infections and its impact on antimicrobial resistance. This supplement will also present new strategies for optimizing antibiotic utilization and improving clinical outcomes. TARGET AUDIENCE This continuing education activity has been designed for managed care physicians and pharmacists who practice in or are interested in the field of infectious disease. EDUCATIONAL OBJECTIVES Upon completion of the activity, participants should be better able to: Explain the various community-acquired respiratory tract infections and current treatment options. Describe the emerging resistance patterns of respiratory tract pathogens to antibiotics in both hospitaland community-acquired infections. Evaluate current and future pharmacologic options for the management of respiratory tract infections by comparing and contrasting antibiotic profile characteristics such as spectrum of coverage, risk of resistance, pharmacokinetics, and pharmacodynamics. Discuss formulary decision-making strategies that may limit antimicrobial resistance and improve outcomes. Discuss the pharmacoeconomic outcomes of various antibiotic regimens. CONTINUING MEDICAL EDUCATION CONTINUING EDUCATION Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and Advanced Concepts Institute. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 category 1 credits toward the AMA Physician s Recognition Award. Each physician should claim only those credits that he/she CONTINUING PHARMACY EDUCATION Accreditation Statement The Philadelphia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Philadelphia College of Pharmacy designates this educational activity (# H01) acceptable for 1.8 continuing education credits (0.18 CEUs). Each pharmacist should claim only those credits that he/she Release date: October 15, Expiration date: October 31, Estimated time to complete activity: 1.75 hours. This program is supported by an educational grant from Sanofi-Aventis Pharmaceuticals. This activity is developed and managed by Advanced Concepts Institute. THE AMERICAN JOURNAL OF MANAGED CARE
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationAccording to a recent National ... PRESENTATION...
... PRESENTATION... in Treating Respiratory Tract Infections in an Age of Antibiotic Resistance Miguel Mogyoros, MD Presentation Summary Managing respiratory tract infections (RTIs) presents many challenges
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationThe World Health Organization has referred to. Antibiotic Resistance: The Iowa Experience DRUG UTILIZATION. Nancy Bell, RPh
DRUG UTILIZATION Antibiotic Resistance: The Iowa Experience Nancy Bell, RPh Background: In the past 10 years, the number of strains of Streptococcus pneumoniae and other common respiratory pathogens that
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationThe Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 09:00 09:20 Registration
More informationReview Article Factors Affecting the Cost Effectiveness of Antibiotics
Chemotherapy Research and Practice Volume 2011, Article ID 249867, 6 pages doi:10.1155/2011/249867 Review Article Factors Affecting the Cost Effectiveness of Antibiotics Steven Simoens Research Centre
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationIs erythromycin bactericidal
Is erythromycin bactericidal Search Comparison of erythromycin, clarithromycin, azithromycin, telithromycin, roxithromycin: mechanism of action, spectrum of activity, side effects, drug interactions. Erythromycin
More informationInfection. Recently introduced antibiotics: a guide for the general physician CME: CLINICAL PRACTICE AND ITS BASIS. Linezolid.
CME: CLINICAL PRACTICE AND ITS BASIS Infection Edited by Andrew Lever MD FRCP, Professor of Infectious Diseases Addenbrooke s Hospital, Cambridge Recently introduced antibiotics: a guide for the general
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 Time Topic/Activity
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One g contains:
More informationWORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives
Objectives To establish the basic pharmacokinetic properties and safety profile of predefined macrolides. To make an inventory of the intrinsic susceptibilities of pathogenic organisms towards macrolides
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationSUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationReport on New Patented Drugs - Ketek
Report on New Patented Drugs - Ketek October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationStewardship: Challenges & Opportunities in the Gulf Region
Stewardship: Challenges & Opportunities in the Gulf Region Mushira Enani, MBBS, FRCPE, FACP,CIC Head- Infectious Disease Section King Fahad Medical City Outline Background of Healthcare system in GCC GCC
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety
More informationAntimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance
Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Natalie Weber, PharmD PGY2 Critical Care Pharmacy Resident September 22, 2016 The speaker has no actual or potential conflicts of
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationPhase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin
ORIGINAL ARTICLE JIACM 2002; 3(4): 360-6 Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin SH Talib*,
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and
More informationTreatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
Journal of Antimicrobial Chemotherapy (2008) 61, 1162 1168 doi:10.1093/jac/dkn073 Advance Access publication 29 February 2008 Treatment costs associated with community-acquired pneumonia by community level
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationHealthcare Facilities and Healthcare Professionals. Public
Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationSECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products
SECTION 3A Criteria for Optional Special Authorization of Select Drug Products Section 3A Criteria for Optional Special Authorization of Select Drug Products CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationCLINICIAN INTERVIEW TREATING RESPIRATORY TRACT INFECTIONS IN THE ERA OF ANTIBIOTIC RESISTANCE. An interview with Richard H. Drew, PharmD, MS, BCPS
TREATING RESPIRATORY TRACT INFECTIONS IN THE ERA OF ANTIBIOTIC RESISTANCE An interview with Richard H. Drew, PharmD, MS, BCPS Dr Richard H. Drew is Infectious Diseases Clinical Pharmacist at Duke University
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More informationTopical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures
Topical Antibiotic Update Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures What do we have? We currently have many highly effective
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More information6/15/2017 PART 1: THE PROBLEM. Objectives. What is Antimicrobial Resistance? Conflicts of Interest Disclosure Statement
Conflicts of Interest Disclosure Statement Getting a grasp on Antibiotic Use and Resistance: Principles of Antimicrobial Stewardship Speaker has nothing to disclose. Jacob M Kesner, PharmD UNMH PGY-2 Infectious
More informationTelephone Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap
Telephone 613-835-9490 Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada Sitemap 12-3-2018 Healthy people commonly aspirate small amounts of oral secretions, but normal defense mechanisms
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationMacrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline
Macrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline JerryM.Zuckerman, MD a,b, *,FoziaQamar, MD b, Bartholomew R.Bono, MD a,b KEYWORDS Macrolides Ketolides
More informationIDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA
page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More informationAntimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationParatek Announces FDA Approval of NUZYRA (Omadacycline)
Paratek Announces FDA Approval of NUZYRA (Omadacycline) Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate
SUMMARY OF PRODUCT CHARACTERISTICS AN: 00221/2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lincocin Forte S Intramammary Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Lincomycin
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More informationEar drops suspension. A smooth, uniform, white to off-white viscous suspension.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:
More informationORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia
ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationCommunity-Acquired Pneumonia: Severity scoring and compliance to BTS guidelines. Julie Harris Antibiotic Pharmacist Hywel Dda Healthboard
Community-Acquired Pneumonia: Severity scoring and compliance to BTS guidelines Julie Harris Antibiotic Pharmacist Hywel Dda Healthboard Plan Background BTS guidelines Differences in opinion Measures introduced
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks Vapo Rub for Cold Symptoms
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More information